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Influence of Antiplatelet Therapy on Cerebral
Micro-emboli After Carotid Endarterectomy Using Postoperative
Transcranial Doppler Monitoring
S. Macdonald
Consultant Vascular Radiologist & Honorary Clinical Senior Lecturer,
Freeman Hospital, Newcastle-upon-Tyne, NE7 7DN, UKThis well-written paper describes a randomised trial
with negative outcomes. Essentially, no difference
was shown in the rate of microembolisation as de-
tected by Transcranial Doppler (TCD) in relation to
three different antiplatelet regimes employed during
carotid endarterectomy. Baring in mind the potential
for negative publication bias for trials without posi-
tive outcomes, there is perhaps a good incentive to
share the data proffered with an audience of vascular
specialists.
The authors quite rightly point out that the study is
underpowered to detect a relationship between clini-
cal adverse cerebral events and antiplatelet regimes.
The study instead hinges on the use of a surrogate
marker of neurological injury utilised in place of
clinical endpoints, namely the rate of TCD- detected
microemboli in the middle cerebral artery ipsilateral
to the carotid artery being treated by endarterectomy.
This surrogate is being increasingly used in studies
of carotid intervention by both carotid endarterectomy
and carotid stenting. Whilst it may be reasonable to do
so, it must be recognised that the absolute numbers of
microemboli detected during carotid endarterectomy
and stenting are discrepant perhaps by a significant or-
der of magnitude (a reasonable body of work suggests
significantly more microemboli when either carotid
angioplasty or indeed, state-of-the-art carotid stenting
is performed, compared with carotid endarterectomy).
Under these circumstances, with the relative paucity
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the trial as presented is underpowered for the use of
this surrogate marker in a way that would not be rele-
vant for a study of carotid stenting. As a pilot study,
though, it provides food for thought.
A number of other points may be raised. Ordinarily,
there may be intuitive concerns about the use of dual
antiplatet agents employed during endarterectomy,
particularly with respect to the greatly feared bleeding
complication rate. Indeed, the rate of bleeding compli-
cation requiring re-exploration of the neck in this
study is 4.9% (5/102), which seems a little high. Two
patients suffering this complication were treated
with asasantin and clopidogrel and two with asasantin
and Rheomacrodex. It is unfortunate, then, that the use
of these two additional antiplatelet strategies did not
result in benefit as judged by a significant reduction
in microembolic signals. Furthermore, the dosing
schedule for Group II, in which clopidogrel was
administered in addition to asasantin is not clearly ra-
tionalised. Clopidogrel was provided at a dose of
75 mg three days prior to endarterectomy. Certainly
for carotid stenting, which we must accept is not the
primary focus of this study, there is Level 1 evidence
to support a much more stringent dual antiplatelet re-
gime. This comprises either 75 mg clopidogrel daily
one week prior to intervention to supplement aspirin
at a dose of at least 75 mg daily with both drugs to con-
tinue for at least 28 days post-stenting or alternatively,
in a more urgent setting, for clopidogrel to be admin-
istered at a dose of 300e600 mg at least 15 hours prior
to the procedure, assuming that the patient, invariably
an arteriopath, is taking aspirin at a dose of at least
144 S. Macdonald75 mg daily. Clearly, a recently endarterectomised ar-
tery will in most cases expose a thrombogenic surface
to the circulation and this may be compounded by the
use of a synthetic patch (albeit selectively applied in
this series). The authors reference the Leicester experi-
ence in which one hundred patients on 150 mg of
aspirin were randomised to 75 mg of clopidogrel or
placebo the night before surgery (reference 27). A
significant reduction in platelet response to adenosine
diphosphate with a 10-fold reduction in the relative
risk of those patients having> 20 emboli on TCD in
the postoperative period was demonstrated. Whilst
the number recruited in the Leicester study is compa-
rable to the trial presented here, the Leicester work
highlights a two-way randomisation process and the
current study a three-way randomisation. The reduced
number in each randomised limb of the current trial
perhaps explains the negative results. However, it does
beg the question; ‘‘Are the authors convinced of the
validity of their chosen antiplatelet dosing schedule?’’
Penultimately, the influence of the heparin regime
selected within this trial on the antiaggregant effect
on the antiplatelets employed is worthy of elaboration.
It is stated simply that 5,000 international units (IU) of
heparin were administered prior to cross-clamping,
that protamine reversal was not used, that platelet ag-
gregation tests were not performed and that the hepa-
rin dose-response relationship was calculated by the
activated clotting time (ACT). The readership must as-
sume that unfractionated heparin was utilised within
this trial and yet the Leicester group elegantly demon-
strated that administration of unfractionated heparin
during the procedural time-frame of carotid endarter-
ectomy significantly increases platelet aggregation in
response to arachidonic acid, despite adequate inhibi-
tion by aspirin administered preoperatively.1 This ap-
parent reversal of antiplatet activity persists into the
immediate post-operative period. Taken to its logical
conclusion, the use of unfractionated heparin withinEur J Vasc Endovasc Surg Vol 34, August 2007this trial may jeopardize the results of a trial relying
on the effect of asasantin as a supplement to additional
antiplatelet agents. Intriguingly, the Leicester group’s
work is referenced on seven occasions but both the po-
tentially harmful effect of unfractionated heparin and
the relatively protective effect of the (as yet unli-
censed) use of intravenous FRACTIONATED heparin
during carotid endarterectomy is overlooked.2
Finally, we must not neglect the issue of aspirin
(and/or asasantin) resistance e this is hinted at in the
discussion section of the paper. Indeed, the aspirin-
resistant population may be at increased risk of
clopidogrel-resistance. The authors have a noble aim e
that of a ‘‘one-size-fits-all’’ antiplatelet regime but
without accurate point-of-care testing for aspirin, asa-
santin and/or clopidogrel resistance (which unfortu-
nately remains elusive) this aim may not realistically
be achieved.
In summary, this trial has failed to show any differ-
ence in the rate of embolisation in the first two hours
after endarterectomy in patients treated with one of
three different antiplatet regimes. This may be be-
cause there is no difference, or it may be because the
trial was underpowered and/or flawed by inappro-
priate choice of pharmacological regime and the
dosing schedule.
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